Current and historical daily PE Ratio for Luye Pharma Group Ltd (
) from 2014 to May 28 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Luye Pharma Group stock (HKSE:02186) PE ratio as of May 28 2024 is 17.31.
More Details
Luye Pharma Group Ltd (HKSE:02186) PE Ratio (TTM) Chart
Luye Pharma Group Ltd (HKSE:02186) PE Ratio (TTM) Historical Data
View and export this data going back to 2014. Start your Free Trial
Total 1213
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Luye Pharma Group PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-28 | 17.3 | 2024-03-19 | 18.8 |
| 2024-05-27 | 17.3 | 2024-03-18 | 19.0 |
| 2024-05-24 | 17.1 | 2024-03-15 | 19.6 |
| 2024-05-23 | 17.3 | 2024-03-14 | 19.6 |
| 2024-05-22 | 17.5 | 2024-03-13 | 19.4 |
| 2024-05-21 | 17.6 | 2024-03-12 | 19.1 |
| 2024-05-20 | 19.1 | 2024-03-11 | 18.4 |
| 2024-05-17 | 19.2 | 2024-03-08 | 17.9 |
| 2024-05-16 | 19.0 | 2024-03-07 | 17.6 |
| 2024-05-14 | 19.1 | 2024-03-06 | 17.9 |
| 2024-05-13 | 19.6 | 2024-03-05 | 17.8 |
| 2024-05-10 | 19.6 | 2024-03-04 | 18.3 |
| 2024-05-09 | 19.6 | 2024-03-01 | 18.6 |
| 2024-05-08 | 19.1 | 2024-02-29 | 18.5 |
| 2024-05-07 | 19.2 | 2024-02-28 | 18.5 |
| 2024-05-06 | 19.2 | 2024-02-27 | 18.4 |
| 2024-05-03 | 19.4 | 2024-02-26 | 18.0 |
| 2024-05-02 | 19.4 | 2024-02-23 | 17.6 |
| 2024-04-30 | 17.8 | 2024-02-22 | 17.6 |
| 2024-04-29 | 17.6 | 2024-02-21 | 17.5 |
| 2024-04-26 | 17.4 | 2024-02-20 | 17.1 |
| 2024-04-25 | 17.3 | 2024-02-19 | 17.2 |
| 2024-04-24 | 17.2 | 2024-02-16 | 17.7 |
| 2024-04-23 | 17.0 | 2024-02-15 | 16.2 |
| 2024-04-22 | 17.1 | 2024-02-14 | 16.0 |
| 2024-04-19 | 16.7 | 2024-02-09 | 16.4 |
| 2024-04-18 | 16.8 | 2024-02-08 | 16.7 |
| 2024-04-17 | 16.9 | 2024-02-07 | 16.5 |
| 2024-04-16 | 16.7 | 2024-02-06 | 16.5 |
| 2024-04-15 | 17.2 | 2024-02-05 | 15.8 |
| 2024-04-12 | 17.6 | 2024-02-02 | 16.0 |
| 2024-04-11 | 18.1 | 2024-02-01 | 16.8 |
| 2024-04-10 | 17.9 | 2024-01-31 | 16.9 |
| 2024-04-09 | 18.1 | 2024-01-30 | 17.6 |
| 2024-04-08 | 17.8 | 2024-01-29 | 18.3 |
| 2024-04-05 | 17.2 | 2024-01-26 | 18.8 |
| 2024-04-03 | 18.0 | 2024-01-25 | 19.0 |
| 2024-04-02 | 18.6 | 2024-01-24 | 19.2 |
| 2024-03-28 | 17.5 | 2024-01-23 | 19.2 |
| 2024-03-27 | 18.2 | 2024-01-22 | 19.2 |
| 2024-03-26 | 18.2 | 2024-01-19 | 19.9 |
| 2024-03-25 | 18.3 | 2024-01-18 | 20.7 |
| 2024-03-22 | 19.0 | 2024-01-17 | 20.6 |
| 2024-03-21 | 19.4 | 2024-01-16 | 21.6 |
| 2024-03-20 | 19.1 | 2024-01-15 | 22.3 |
Luye Pharma Group Ltd (HKSE:02186) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Luye Pharma Group Ltd
NAICS : 325412
SIC : 2834
ISIN : BMG570071099
Share Class Description:
HKSE:02186: Ordinary Shares - Class HCompare
Compare
Traded in other countries / regions
02186.Hong KongLUP.GermanyLYPHF.USA IPO Date
2014-07-09Description
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company's highest revenue share comes from oncology drugs, followed by central nervous system drugs. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, Cardiovascular system drugs, Alimentary tract and metabolism drugs and Central nervous system drugs. It derives maximum revenue from the sale of Oncology drugs.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers